The HEALEY ALS Platform Trial enrolled 250 participants in under five months from first participant dosing, marking the fastest site activation/enrolment to date. Topline efficacy and safety results for NUZ-001 are now expected in late Q2 CY2027, implying a longer wait for clinical readouts but continued recruitment momentum.
The HEALEY ALS Platform Trial enrolled 250 participants in under five months from first participant dosing, marking the fastest site activation/enrolment to date. Topline efficacy and safety results for NUZ-001 are now expected in late Q2 CY2027, implying a longer wait for clinical readouts but continued recruitment momentum.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialOverall Sentiment
mildly positive
Sentiment Score
0.18
